Substance / Medication

Fedratinib

Overview

Active Ingredient
fedratinib
RxNorm CUI
2197490

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults.
Chen Yizhe, Wyatt David, Attanasio Massimo et al. · Cancer Chemother Pharmacol · 2024
PMID: 37955741RCTFull text (PMC)
Exposure-response relationship of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
Chen Yizhe, Li Yan, Xue Yongjun et al. · Br J Clin Pharmacol · 2025
PMID: 40485284Trial
Pharmacokinetics, safety, and tolerability of fedratinib in adults with moderate and severe hepatic impairment: results from the phase 1 FEDR-CP-001 trial.
Chen Yizhe, Preston Richard A, Marbury Thomas et al. · Cancer Chemother Pharmacol · 2025
PMID: 40601051Trial
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
Gupta Vikas, Yacoub Abdulraheem, Mesa Ruben A et al. · Leuk Lymphoma · 2024
PMID: 38838026Trial
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
Chen Yizhe, Ogasawara Ken, Wood-Horrall Rebecca et al. · Cancer Chemother Pharmacol · 2022
PMID: 36001108TrialFull text (PMC)
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
Ogasawara Ken, Xu Christine, Yin Jian et al. · Clin Pharmacol Drug Dev · 2021
PMID: 32673446Trial
Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
Ogasawara Ken, Kam Jeanelle, Thomas Mark et al. · Cancer Chemother Pharmacol · 2021
PMID: 34019108Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Fedratinib (substance)
SNOMED CT
789359000
UMLS CUI
C3886623
RxNorm CUI
2197490

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.